Company: STAA
Filing Date: 2025-10-16
Form Type: DEFA14A
Source: 0001193125-25-241528
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-16
Form: DEFA14A
Chunk 1
---
 intended as a proposal.” The email was not followed up on by Party C. The facts remain:

| • |     | Despite Broadwood’s assertions, STAAR has not received any proposal to acquire the Company other than from 
 Alcon, including during the 45-day “window shop” period.                                                   |

| • |     | The outreach from Parties A, B, and C were not offers. |

We urge all STAAR stockholders not to be misled by Broadwood. STAAR is confident that the Alcon transaction maximizes value for STAAR stockholders, is the only merger transaction available to the Company and if it is not approved, the value of your shares is at risk of declining substantially. Time is short. The Special Meeting is fast approaching. We encourage all STAAR stockholders to vote ‘FOR’ the Alcon merger on the WHITE proxy card TODAY.

STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote on the Alcon merger. Stockholders of record as of the close of business on September 12, 2025, are entitled to vote at the meeting. The STAAR Board of Directors has unanimously approved the merger and recommended that all STAAR stockholders vote “FOR” the merger proposal on the WHITE proxy card TODAY. Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:

| • |     | For stockholders: +1 877-750-8233 
 (toll-free)                       |

| • |     | For banks and brokerage firms: +1 
 212-750-5833                      |

About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer ®Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL ™product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs